Search results
Results from the WOW.Com Content Network
In the European Union, the combination is indicated for the treatment of COVID‑19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) who do not require supplemental oxygen and who are at high increased risk of progressing to severe COVID‑19; [10] and for the prevention of COVID‑19 in people aged twelve years of age and older weighing at least 40 kilograms ...
Sipavibart, sold under the brand name Kavigale, is a medication used for the prevention of COVID-19 in people who are immunocompromised. [1] Sipavibart is a recombinant human IgG1 monoclonal antibody that provides passive immunization against SARS-CoV-2 by binding its spike protein receptor binding domain.
Individuals may experience distress from quarantine, travel restrictions, side effects of treatment, or fear of the infection itself. To address these concerns, the National Health Commission of China published a national guideline for psychological crisis intervention on 27 January 2020.
A World Health Organization infographic that states that hydroxychloroquine does not prevent illness or death from COVID-19. Chloroquine and hydroxychloroquine are anti-malarial medications also used against some auto-immune diseases. [1] Chloroquine, along with hydroxychloroquine, was an early experimental treatment for COVID-19. [2]
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
The EMA also initiated an assessment for all COVID‑19 vaccines used in the EU for immune thrombocytopenia (ITP), described as low blood platelet levels that could lead to bruising and bleeding, as a possible side effect, whilst also stating that up to this point no link with any COVID‑19 had been established. [12]
Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). [10] [11] It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor [6] that is designed to bind to the fusion protein on the surface of the RSV virus.
Anxiety about COVID-19 makes people more willing to "try anything" that might give them a sense of control of the situation, making them easy targets for scams. [5] Many false claims about measures against COVID-19 have circulated widely on social media, but some have been circulated by text, on YouTube, and even in some mainstream media ...